Anavex Life Sciences (NASDAQ:AVXL) Share Price Down 6.1%


The share price of Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Rating) was down 6.1% in Friday’s session. The stock traded as low as $9.78 and last traded at $9.81. About 18,066 shares changed hands during trading, down 98% from the average daily volume of 912,004 shares. The stock had previously closed at $10.45.

A number of research companies have recently published reports on AVXL. HC Wainwright reworded a “buy” rating and posted a $42.00 price target on Anavex Life Sciences shares in a Wednesday, March 16 research report. StockNews.com kicked off coverage of Anavex Life Sciences in a Thursday, March 31 report. They issued a “sell” rating on the stock. Finally, Berenberg Bank launched coverage on Anavex Life Sciences in a report on Thursday. They issued a “buy” rating and a price target of $40.00 on the stock. One analyst gave the stock a sell rating and four gave the company a buy rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

The company has a market capitalization of $787.26 million, a price-earnings ratio of -17.84 and a beta of 0.92. The company’s 50-day moving average price is $8.93 and its two-hundred-day moving average price is $11.83.

Anavex Life Sciences (NASDAQ:AVXL – Get Rating) last announced its results on Tuesday, May 10. The biotech company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.02. During the same quarter last year, the company posted ($0.12) EPS. Stock analysts predict that Anavex Life Sciences Corp. will show an EPS of -0.6 for the current year.

Separately, director Athanasios Skarpelos sold 50,000 shares of the company in a transaction dated Wednesday, May 25. The shares were sold at an average price of $9.06, for a total value of $453,000.00. Following the completion of the sale, the administrator now owns 1,306,458 shares of the company, valued at $11,836,509.48. The sale was disclosed in a legal filing with the SEC, which is available on the SEC’s website. 11.00% of the shares are held by insiders of the company.

Hedge funds have recently been buying and selling shares of the company. Apella Capital LLC acquired a new equity stake in Anavex Life Sciences during Q1 worth approximately $124,000. Dana Investment Advisors Inc. bought a new position in Anavex Life Sciences stock during Q1 worth approximately $132,000. Atria Wealth Solutions Inc. bought a new position in Anavex Life Sciences stock during Q1 worth approximately $136,000. Point72 Hong Kong Ltd increased its stake in Anavex Life Sciences shares by 151.6% during the 4th quarter. Point72 Hong Kong Ltd now owns 9,009 shares of the biotech company worth $156,000 after buying 5,428 more shares last quarter. Finally, Liberty One Investment Management LLC increased its stake in Anavex Life Sciences shares by 23.3% during the 1st quarter. Liberty One Investment Management LLC now owns 13,119 shares of the biotech company worth $161,000 after buying 2,479 additional shares last quarter. Institutional investors hold 29.01% of the company’s shares.

Company Profile Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in a phase III clinical trial for the treatment of Alzheimer’s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; phase II clinical trial for the treatment of Parkinson’s disease; and preclinical clinical trials to treat epilepsy, infantile spasms, fragile X syndrome, Angelman syndrome, multiple sclerosis and tuberous sclerosis complex.

Featured articles



Get news and reviews for Anavex Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Anavex Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.

About Michael Bill

Check Also

Types, how they work, side effects

Nerve pain, also called neuropathic pain or neuropathy, refers to painful sensations around nerves. A …